TABLE 4.
Analysis of samples with discrepant results between the UL55/UL123 TaqMan assay and pp65 antigenemia on a study subject levela
| Result type (pertinent data) | Evidence of CMV in the same patient at different time points or sites
|
|||||
|---|---|---|---|---|---|---|
| Subject/donor setting and serostatusb | Total no. of subjects | pp65 antigenemia
|
PCR
|
|||
| n | % | n | % | |||
| PCR positive-pp65 antigenemia negative (n = 122 samples; 57 patients; median DNA load, 1,150 copies/ml; range, 40 to 226,300) | HSCT R+ | 55 | 41 | 75.5 | 48 | 87.3 |
| HSCT D+/R− | 1 | 1 | 100.0 | 1 | 100.0 | |
| HSCT D−/R− or R-auto | 0 | |||||
| HIV/CMV+ | 0 | |||||
| PCR negative-pp65 antigenemia positive (n = 29 samples; 25 patients; median pp65 antigenemia, 0.5 cells/slide; range, 0.5 to 32) | HSCT R+ | 19 | 12 | 63.2 | 14 | 73.7 |
| HSCT D+/R− | 2 | 0 | 0 | 0 | 0 | |
| HSCT D−/R− or R-auto | 4 | 0 | 0 | 0 | 0 | |
| HIV/CMV+ | 1 | 0 | 0 | 0 | 0 | |
a
Subjects were examined for evidence of CMV at different time points after transplant and by different detection methods.
b
D, donor serostatus; R, recipient serostatus; auto, autologous.